NEOG
Neogen Corporation
NEOG has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NEOG overall, supported by stronger fundamentals and stronger modeled upside.
NEOG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
NEOG's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NEOG PE Valuation
NEOG has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NEOG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for NEOG, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NEOG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.26 | +$4.54 |
| Q2 2026 | -$0.04 | +$4.99 |
| Q1 2026 | -$2.80 | -$0.57 |
| Q4 2025 | -$2.77 | -$0.58 |
| Q3 2025 | -$4.80 | -$4.69 |
| Q2 2025 | -$5.03 | -$4.99 |
| Q1 2025 | -$2.23 | -22400% |
| Q4 2024 | -$2.19 | -3750% |
NEOG is still losing money, but far less than before: $0.26 per share over the past year, against $5.03 at its worst in mid-2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NEOG on earnings quality, reporting a profit while its opponent remains loss making.
NEOG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.8M | +6.5% |
| Q2 2026 | $225.3M | -0.1% |
| Q1 2026 | $211.2M | -4.4% |
| Q4 2025 | $224.7M | -2.8% |
| Q3 2025 | $209.2M | -3.6% |
| Q2 2025 | $225.5M | -4.8% |
| Q1 2025 | $221M | -3.4% |
| Q4 2024 | $231.3M | +0.7% |
NEOG's revenue grew through 2023 and has held roughly level since: $223M last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +6.9 points |
| Q2 2026 | 1.4% | +273 points |
| Q1 2026 | -1.6% | -4 points |
| Q4 2025 | -2.4% | +195 points |
| Q3 2025 | -7.7% | -8.7 points |
| Q2 2025 | -271% | -277 points |
| Q1 2025 | 2.5% | -2.8 points |
| Q4 2024 | -198% | -204 points |
NEOG's operating margin was −0.8% last quarter, up 6.9 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NEOG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NEOG on profitability, with a higher operating margin.
NEOG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | +$17.8M |
| Q2 2026 | $26.2M | +6353% |
| Q1 2026 | $11.1M | +$24.6M |
| Q4 2025 | $7.8M | -66% |
| Q3 2025 | -$13.1M | +$43.2M |
| Q2 2025 | $406K | -84% |
| Q1 2025 | -$13.5M | +$48.8M |
| Q4 2024 | $23.1M | +$31.8M |
NEOG's free cash flow has turned positive after four years mostly in the red: $50M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NEOG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +600K shares |
| 1 year | +0.4% | +765K shares |
| 3 years | +0.6% | +1.3M shares |
| 5 years | +102% | +110M shares |
| Available history | +106% | +112M shares |
NEOG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NEOG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 12.7x | High |
| Q2 2026 | 6.4x | High |
| Q3 2024 | 4.8x | High |
| Q2 2024 | 4.1x | High |
| Q1 2024 | 3.9x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q3 2023 | 4.4x | High |
| Q2 2023 | 5.7x | High |
NEOG's net debt is about 13 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NEOG on leverage, with a lower net debt burden relative to earnings.
NEOG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 25.0 | Neutral |
NEOG's weekly RSI is 51 (neutral) and its Stochastic is 25 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NEOG PE vs Healthcare Sector
| Metric | NEOG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEOG has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NEOG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 7.3% below |
| 20 week MA | $11.5 | 2.9% below |
| 50 week MA | $10.1 | 11% above |
| 100 week MA | $8.62 | 30% above |
| 200 week MA | $12.9 | 13% below |
NEOG's trend is mixed: it's above two of its five weekly moving averages, and 13% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NEOG on trend strength, trading above more of its moving averages.
NEOG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.5 | $40.5 | +24% |
| 2021 | $40.5 | $44.4 | +9.7% |
| 2022 | $44.4 | $14.9 | -67% |
| 2023 | $14.9 | $20.1 | +35% |
| 2024 | $20.1 | $12.4 | -38% |
| 2025 | $12.4 | $7.13 | -43% |
| 2026 YTD | $7.13 | $11.2 | +57% |
NEOG is up 57% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NEOG on returns for 2026, with the stronger performance.